Linked Life Data

19997960

Source:http://linkedlifedata.com/resource/pubmed/id/19997960

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19997960rdf:typepubmed:Citationlld:pubmed
pubmed-article:19997960lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19997960lifeskim:mentionsumls-concept:C0024623lld:lifeskim
pubmed-article:19997960lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:19997960lifeskim:mentionsumls-concept:C0069717lld:lifeskim
pubmed-article:19997960lifeskim:mentionsumls-concept:C0671970lld:lifeskim
pubmed-article:19997960lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:19997960lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:19997960lifeskim:mentionsumls-concept:C0995188lld:lifeskim
pubmed-article:19997960lifeskim:mentionsumls-concept:C1956962lld:lifeskim
pubmed-article:19997960lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:19997960lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:19997960lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:19997960lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:19997960pubmed:issue2lld:pubmed
pubmed-article:19997960pubmed:dateCreated2011-2-11lld:pubmed
pubmed-article:19997960pubmed:abstractTextWe evaluated the efficacy and safety of cetuximab in combination with XELOX [XELoda® (capecitabine) and OXaliplatin] in advanced gastric cancer (AGC) patients. The objectives were to evaluate overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety of cetuximab plus XELOX.lld:pubmed
pubmed-article:19997960pubmed:languageenglld:pubmed
pubmed-article:19997960pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19997960pubmed:citationSubsetIMlld:pubmed
pubmed-article:19997960pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19997960pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19997960pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19997960pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19997960pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19997960pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19997960pubmed:statusMEDLINElld:pubmed
pubmed-article:19997960pubmed:monthAprlld:pubmed
pubmed-article:19997960pubmed:issn1573-0646lld:pubmed
pubmed-article:19997960pubmed:authorpubmed-author:KangYoon-KooY...lld:pubmed
pubmed-article:19997960pubmed:authorpubmed-author:LimHo YoungHYlld:pubmed
pubmed-article:19997960pubmed:authorpubmed-author:KimChulClld:pubmed
pubmed-article:19997960pubmed:authorpubmed-author:RyooBaek-Yeol...lld:pubmed
pubmed-article:19997960pubmed:authorpubmed-author:ParkYoung...lld:pubmed
pubmed-article:19997960pubmed:authorpubmed-author:LeeJae-LyunJLlld:pubmed
pubmed-article:19997960pubmed:authorpubmed-author:RyuMin-HeeMHlld:pubmed
pubmed-article:19997960pubmed:authorpubmed-author:KimTae WonTWlld:pubmed
pubmed-article:19997960pubmed:authorpubmed-author:ChangHeung...lld:pubmed
pubmed-article:19997960pubmed:authorpubmed-author:KangHye JinHJlld:pubmed
pubmed-article:19997960pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19997960pubmed:volume29lld:pubmed
pubmed-article:19997960pubmed:ownerNLMlld:pubmed
pubmed-article:19997960pubmed:authorsCompleteYlld:pubmed
pubmed-article:19997960pubmed:pagination366-73lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:meshHeadingpubmed-meshheading:19997960...lld:pubmed
pubmed-article:19997960pubmed:year2011lld:pubmed
pubmed-article:19997960pubmed:articleTitleA prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.lld:pubmed
pubmed-article:19997960pubmed:affiliationDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea.lld:pubmed
pubmed-article:19997960pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19997960pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:19997960pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:19997960pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed